| Retinal Vein Occlusion |
2013-004656-38: Assessment of the suitability of serum VEGF level as diagnostic factor in macula edema under therapy with Lucentis® (ranibizumab) Bewertung der Eignung des Serum VEGF Spiegels als diagnostischer Faktor bei einem Makulaödem unter Therapie mit Lucentis® (Ranibizumab) |
|
|
| Ongoing | 4 | 30 | Europe | Injection, Lucentis Injektionslösung | Prof. Dr. Karl-Heinz Emmerich, Novartis Pharma GmbH | Central retinal vein occlusionRetinal vein occlusion, Occlusion of a vein of the retina, Diseases [C] - Eye Diseases [C11] | | | | |
2014-002790-11: Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab Evaluierung eines „Treat-and-Extend“ Schemas bei Patienten mit retinalem Venenverschluss mit und ohne Laserphotokoagulation von ischämischen Netzhautarealen |
|
|
| Ongoing | 4 | 60 | Europe | Solution for injection, Lucentis | Ludwig-Maximilians Universität München, Novartis | Makulaödem nach retinalem Venenverschluss (CRVO), Auftreten einer Schwellung (Ödem) der Netzhaut nach dem Verschluss des ableitenden Gefäßes und nachfolgender Flüssigkeitsansammlung im Gewebe des Auges, Diseases [C] - Eye Diseases [C11] | | | | |
2014-000975-21: Study to evaluate the effectiveness of aflibercept in patients with macular edema secondary to central retinal vein occlusion. Estudio para evaluar la eficacia de aflibercept en pacientes con edema macular secundario a oclusión de la vena central de la retina. |
|
|
| Ongoing | 4 | 50 | Europe | Eylea, Eylea, Eylea, Eylea | Fundación Retinaplus +, Bayer | Macular edema secondary to central retinal vein occlusion. Edema macular secundario a oclusión de la vena central de la retina. | | | | |
2020-005449-18: Spontaneous retinal artery pulses as a prognostic determinant of central retinal vein occlusions in patients with and without intravitreal aflibercept injections Pulsations artérielles rétiniennes spontanées (PARS) en tant que déterminant pronostique des occlusions de la veine centrale de la rétine (OVCR) chez les patients traités ou non par injections intravitréennes d’aflibercept |
|
|
| Not yet recruiting | 4 | 60 | Europe | Solution for injection, Eylea 40 mg/mL, solution injectable en seringue préremplie | Hôpital Fondation A. de Rothschild / Service de recherche clinique, Bayer Healthcare | Central retinal vein occlusions Occlusions de la veine centrale de la rétine (OVCR), Central retinal vein occlusions Occlusions de la veine centrale de la rétine (OVCR), Diseases [C] - Eye Diseases [C11] | | | | |
DETeR, NCT04563299: Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections |
|
|
| Terminated | 4 | 10 | US | Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate | Retina Vitreous Associates of Florida, Ocular Therapeutix, Inc. | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 02/23 | 02/23 | | |
BEACON, NCT04592419 / 2020-001061-37: A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) |
|
|
| Completed | 3 | 568 | Europe, US, RoW | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Macular Edema, Retinal Vein Occlusion | 06/22 | 01/23 | | |
| Completed | 3 | 553 | Europe, Japan, US, RoW | Faricimab, VABYSMO®, faricimab-svoa, RO6867461, RG7716, Aflibercept, Eylea, Sham Procedure | Hoffmann-La Roche, Chugai Pharmaceutical | Macular Edema, Branch Retinal Vein Occlusion | 07/22 | 06/23 | | |
COMINO, NCT04740931 / 2020-000441-13: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion |
|
|
| Completed | 3 | 729 | Europe, Japan, US, RoW | Faricimab, VABYSMO®, faricimab-svoa, RG7716, RO6867461, Aflibercept, Eylea, Sham Procedure | Hoffmann-La Roche, Chugai Pharmaceutical | Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion | 08/22 | 07/23 | | |
NORSE SEVEN, NCT05112861: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders |
|
|
| Active, not recruiting | 3 | 120 | US | bevacizumab, ONS-5010 | Outlook Therapeutics, Inc. | Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema | 03/25 | 03/25 | | |
QUASAR, NCT05850520: A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) |
|
|
| Recruiting | 3 | 822 | Europe, Japan, US, RoW | Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein | Bayer, Regeneron Pharmaceuticals | Macular Edema Secondary to Retinal Vein Occlusion | 11/24 | 05/25 | | |
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss |
|
|
| Recruiting | 3 | 350 | RoW | 601 1.25mg, 601, ranibizumab 0.5mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 12/25 | 12/25 | | |
2012-005439-10: Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusion Wiederbehandlung mit Ranibizumab bei Patienten mit Makulaödem infolge eines Venenastverschlusses nach morphologischen Netzhautveränderungen erhoben mittels optischer Kohärenztomographie (OCT) |
|
|
| Ongoing | 2 | 24 | Europe | Ranibizumab, Lucentis (Ranibizumab), Lucentis (Ranibizumab) | University of Leipzig Ritterstr. 26, 04109 Leipzig, Novartis | macular edema secondary to branch retinal vein occlusion (BRVO) Makulaödem bei Venenastverschluss | | | | |
2017-001143-12: A Pilot Study for the Evaluation of Minocycline in the Treatment of Central Retinal Vein Occlusions |
|
|
| Not yet recruiting | 2 | 20 | Europe | Minocycline, Capsule, Minocycline | The National Eye Institute, The National Eye Institute | Central Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diseases [C] - Eye Diseases [C11] | | | | |
2017-001179-21: A Pilot Study for the Evaluation of Minocycline in the Treatment of Branch Retinal Vein Occlusions |
|
|
| Not yet recruiting | 2 | 20 | Europe | Minocycline, Capsule, Minocycline | The National Eye Institute, The National Eye Institute | Branch Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Diseases [C] - Eye Diseases [C11] | | | | |
NCT04667910: 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) |
|
|
| Not yet recruiting | 2 | 60 | RoW | 601 1.25mg, Drug 601, Ranibizuman 0.5 mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Central Retinal Vein Occlusion | 07/22 | 01/23 | | |
NCT04667897: 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) |
|
|
| Not yet recruiting | 2 | 60 | RoW | 601 1.25mg, Drug 601, Ranibizuman 0.5 mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 07/22 | 01/23 | | |
NCT05532735: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion |
|
|
| Active, not recruiting | 2 | 16 | US | ANXV | Annexin Pharmaceuticals AB, InFocus Clinical Research | Retinal Vein Occlusion | 07/24 | 07/24 | | |
NCT06176963: A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO |
|
|
| Completed | 2 | 34 | Europe | SB11 PFS, Ranibizumab | Samsung Bioepis Co., Ltd. | Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion | 11/23 | 12/23 | | |
NCT04576689: Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy |
|
|
| Completed | 2 | 60 | Canada, RoW | IBE-814 70ug, Low dose, IBE-814 140ug, High dose | Ripple Therapeutics Pty Ltd, Novotech (Australia) Pty Limited | Diabetic Macular Oedema, Retinal Vein Occlusion With Macular Oedema | 04/23 | 03/24 | | |
| Completed | 1/2 | 16 | US | Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy | The Emmes Company, LLC, National Eye Institute (NEI), University of California, Davis | Central Retinal Vein Occlusion | 11/23 | 11/23 | | |
NCT04120311: Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole |
|
|
| Active, not recruiting | 1 | 2 | US | Episcleral Dexamethasone, Sequestered Transscleral, Controlled-Release Dexamethasone, Sustained Release Transscleral Dexamethasone | Targeted Therapy Technologies, LLC | Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis | 09/24 | 09/24 | | |
NCT05099094: VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases |
|
|
| Recruiting | 1 | 18 | RoW | BD311 | Shanghai BDgene Co., Ltd., Eye & ENT Hospital of Fudan University | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 09/23 | 09/23 | | |
NCT04120636: Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole |
|
|
| Active, not recruiting | 1 | 3 | US | Episcleral Celecoxib, Sustained Release Transscleral Celecoxib | Targeted Therapy Technologies, LLC | Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis | 06/24 | 06/24 | | |
NCT04008121: Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium |
|
|
| Not yet recruiting | 1 | 10 | US | Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system | MediBeacon | Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration | 12/24 | 12/24 | | |
NAAVA, NCT04137120: Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice |
|
|
| Completed | N/A | 73 | RoW | Aflibercept (BAY86-5321, Eylea), Eylea®; Eylia®; Wetlia®; VEGF Trap-Eye | Bayer | Retinal Disease | 08/22 | 02/23 | | |
HERMES Study, NCT02880644: Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept |
|
|
| Completed | N/A | 65 | Europe | | Centre Hospitalier Intercommunal Creteil, Bayer, Association Clinique Thérapeutique Infantile du val de Marne | Retinal Vein Occlusion | 11/22 | 11/22 | | |
NCT06213896: Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images |
|
|
| Completed | N/A | 1528 | RoW | Mydriatic Agent, Tropicamide drops, Color Fundus Photography, EyeCheckup v2.0 | URAL Telekomunikasyon San. Trade Inc. | Glaucoma, Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy, Diabetic Macular Edema, Eye Diseases | 04/24 | 04/24 | | |
NCT06332690: OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Retinal Vascular Diseases - DME and RVO |
|
|
| Recruiting | N/A | 50 | Europe | dexamethasone implant | IRCCS Multimedica, AbbVie | Diabetic Macular Edema, Macular Edema Due to Diabetes Mellitus, Retinal Vein Occlusion | 06/25 | 12/25 | | |
AIRSPEED, NCT06495203: A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO |
|
|
| Completed | N/A | 1350 | Canada | anti-VEGF treatment | Bayer | Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion | 02/24 | 02/24 | | |
PULSOV, NCT04793100: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections |
|
|
| Active, not recruiting | N/A | 60 | Europe | Ophthalmologic exam at inclusion and 12 months after CRVO, Treatment standardization with aflibercept | Fondation Ophtalmologique Adolphe de Rothschild, Bayer | Central Retinal Vein Occlusion | 03/25 | 03/25 | | |
NCT06439576: Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) |
|
|
| Recruiting | N/A | 1000 | RoW | Faricimab, VABYSMO® | Hoffmann-La Roche, Shanghai Roche Pharmaceutical Co., Ltd | Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion | 11/27 | 11/27 | | |
| Recruiting | N/A | 6000 | Europe, Canada, Japan, US, RoW | Faricimab, VABYSMO™, RO6867461, RG7716, Port Delivery System with Ranibizumab, SUSVIMO™, RG6321 | Hoffmann-La Roche | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion | 12/26 | 12/27 | | |